Advice
in the absence of a submission from the holder of the marketing authorisation:
durvalumab (Imfinzi®) is not recommended for use within NHSScotland.
Indication under review: durvulumab in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice620KB (PDF)
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2434
- Indication:
Durvalumab in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 November 2021